No Data
No Data
Baird Maintains Envista Holdings(NVST.US) With Hold Rating, Cuts Target Price to $17
Baird analyst Jeff Johnson maintains $Envista Holdings(NVST.US)$ with a hold rating, and adjusts the target price from $19 to $17.According to TipRanks data, the analyst has a success rate of 52.8%
Executive Reshuffles: Otis Worldwide, HSBC and Rockwell Automation in Focus
Envista Holdings: Hold Rating Maintained Amidst Executive Appointments and Uncertain Impact on Financial Performance
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Solid Biosciences (SLDB) and Lexeo Therapeutics, Inc. (LXEO)
Evercore Maintains Envista Holdings(NVST.US) With Buy Rating, Cuts Target Price to $19
Evercore analyst Elizabeth Anderson CFA maintains $Envista Holdings(NVST.US)$ with a buy rating, and adjusts the target price from $57 to $19.According to TipRanks data, the analyst has a success
BofA Securities Maintains Envista Holdings(NVST.US) With Buy Rating, Maintains Target Price $22
BofA Securities analyst Allen Lutz maintains $Envista Holdings(NVST.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 48.2%